Integrating rapamycin with novel PI3K/Akt/mTOR inhibitor microRNAs on NOTCH1-driven T-cell acute lymphoblastic leukemia (T-ALL).
Fateme ArjmandSamaneh ShojaeiMitra KhaliliHossein DinmohammadiBehzad PoopakSamira Mohammadi-YeganehYousef MortazaviPublished in: BioImpacts : BI (2023)
These preliminary results highlight the potential for improving T-ALL treatment through multi-targeted therapeutic strategies involving rapamycin and miR-3143/miR-3182.